secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0000875320-23-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B
------------------------------------------------------------------------------

- Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.
- Q4 product revenue $2.30B (+11% YoY); GAAP diluted EPS $3.15, non-GAAP $3.76.
- FY2023 product revenue guidance of $9.55B-$9.7B, implying 7-9% growth.
- Exa-cel regulatory submissions validated in EU and UK; US rolling BLA underway.
- CF drug TRIKAFTA/KAFTRIO generated $7.69B in FY22, up 35% from $5.70B in FY21.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/vrtx-20230207.htm
  HTML page:      https://secwatch.observer/filing/0000875320-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer